Exchange: NASDAQ·Updated 07:30 PM EST

TYRA News

News
all
press releases
Tyra Biosciences (NASDAQ:TYRA) Stock Picked Up by Analysts at Guggenheim
Guggenheim started coverage on Tyra Biosciences in a research note on Friday. They issued a "buy" rating and a $55.00 price target for the company...
MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Stock Picked Up by Analysts at Guggenheim
Guggenheim started coverage on Tyra Biosciences in a research note on Friday. They issued a "buy" rating and a $55.00 price target for the company...
MarketBeat
More News
Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent HighlightsPR NewswireCARLSBAD, Calif., Nov. 10, 2026 Reported initial Phase 2 SURF302 results for oraldabogratinib in FGFR3-altered low-grade...
PR Newswire
Tyra Biosciences to Participate in Upcoming Investor Conferences Tyra Biosciences to Participate in Upcoming Investor ConferencesPR NewswireCARLSBAD, Calif., Nov. 5, 2026 CARLSBAD, Calif., Nov. 5, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAPR NewswireNEW YORK, Oct. 15, 2026NEW YORK, Oct. 15, 2026 /PRNewswire...
PR Newswire
Tyra Biosciences (TYRA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAPR NewswireNEW YORK, Oct. 8, 2026NEW YORK, Oct. 8, 2026 /PRNewswire...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAPR NewswireNEW YORK, Oct. 1, 2026NEW YORK, Oct. 1, 2026 /PRNewswire...
PR Newswire
Nasdaq fell 1%, while Elmet surged 50.6% on $450M DoD funding plans; Rum, SailPoint, Tyra and cybersecurity stocks also rallied.read more...
Benzinga
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsPR NewswireCARLSBAD, Calif., Sept. 14, 2026 CARLSBAD, Calif., Sept. 14, 2026 /PRNewswire/ -- Tyra...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAPR NewswireNEW YORK, Sept. 10, 2026 NEW YORK, Sept. 10, 2026 /PRNewswire...
PR Newswire

Advertisement|Remove ads.